Kings Fund 28 October 2020
- This briefing describes the processes that decide whether NHS services in England will pay for patients to receive new, patented drugs, from the initial development and testing of drugs, to the National Institute for Health and Care Excellence’s (NICE’s) appraisal of their effectiveness and negotiations between the NHS and pharmaceutical companies to agree prices.
